Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
Georgia Deliyannis,Chinn Yi Wong,Paula Ellenberg,Tim Smith,Marianne Gillard,Ester Lopez,Julie McAuley,Chee Wah Tan,Weiguang Zeng,Mason Littlejohn,Runhong Zhou,Jasper Fuk-Woo Chan,Richard Bowen,Elizabeth Vincan,Joseph Torresi,Katherine Kedzierska,Kanta Subbarao,Marc Pellegrini,Trent Munro,Terry Nolan,Steven Rockman,Nicholas A. Gherardin,Samantha L. Grimley,James P. Cooney,Samuel J. Redmond,Kathryn C. Davidson,Francesca L. Mordant,Jing J. Wang,Zhi-wei Chen,Airn E. Hartwig,Jason M. Mackenzie,Colin W. Pouton,Tom P. Gordon,Lin-fa Wang,Stephen J. Kent,Adam K. Wheatley,Sharon R. Lewin,Amy W. Chung,David C. Jackson,Damian F.J. Purcell,Dale I. Godfrey
DOI: https://doi.org/10.1016/j.ebiom.2023.104574
IF: 11.205
2023-06-01
EBioMedicine
Abstract:BACKGROUND: The SARS-CoV-2 global pandemic has fuelled the generation of vaccines at an unprecedented pace and scale. However, many challenges remain, including: the emergence of vaccine-resistant mutant viruses, vaccine stability during storage and transport, waning vaccine-induced immunity, and concerns about infrequent adverse events associated with existing vaccines.METHODS: We report on a protein subunit vaccine comprising the receptor-binding domain (RBD) of the ancestral SARS-CoV-2 spike protein, dimerised with an immunoglobulin IgG1 Fc domain. These were tested in conjunction with three different adjuvants: a TLR2 agonist R4-Pam2Cys, an NKT cell agonist glycolipid α-Galactosylceramide, or MF59® squalene oil-in-water adjuvant, using mice, rats and hamsters. We also developed an RBD-human IgG1 Fc vaccine with an RBD sequence of the immuno-evasive beta variant (N501Y, E484K, K417N). These vaccines were also tested as a heterologous third dose booster in mice, following priming with whole spike vaccine.FINDINGS: Each formulation of the RBD-Fc vaccines drove strong neutralising antibody (nAb) responses and provided durable and highly protective immunity against lower and upper airway infection in mouse models of COVID-19. The 'beta variant' RBD vaccine, combined with MF59® adjuvant, induced strong protection in mice against the beta strain as well as the ancestral strain. Furthermore, when used as a heterologous third dose booster, the RBD-Fc vaccines combined with MF59® increased titres of nAb against other variants including alpha, delta, delta+, gamma, lambda, mu, and omicron BA.1, BA.2 and BA.5.INTERPRETATION: These results demonstrated that an RBD-Fc protein subunit/MF59® adjuvanted vaccine can induce high levels of broadly reactive nAbs, including when used as a booster following prior immunisation of mice with whole ancestral-strain spike vaccines. This vaccine platform offers a potential approach to augment some of the currently approved vaccines in the face of emerging variants of concern, and it has now entered a phase I clinical trial.FUNDING: This work was supported by grants from the Medical Research Future Fund (MRFF) (2005846), The Jack Ma Foundation, National Health and Medical Research Council of Australia (NHMRC; 1113293) and Singapore National Medical Research Council (MOH-COVID19RF-003). Individual researchers were supported by an NHMRC Senior Principal Research Fellowship (1117766), NHMRC Investigator Awards (2008913 and 1173871), Australian Research Council Discovery Early Career Research Award (ARC DECRA; DE210100705) and philanthropic awards from IFM investors and the A2 Milk Company.
medicine, research & experimental